Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d...
Transcript of Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d...
![Page 1: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/1.jpg)
Janis K. Fraser, Ph.D.
July 13, 2011 Webinar
© 2011 by Fish & Richardson P.C.
Pfizer v. Ranbaxy: How NOT
to Write Dependent Claims
1
![Page 2: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/2.jpg)
Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006)
• ANDA case regarding generic Lipitor® (atorvastatin)
• Lower court found two patents infringed and not invalid
• Federal Circuit affirmed as to Pfizer‟s US 4,681,893 (so Ranbaxy lost in the short term)
• Federal Circuit reversed regarding validity of claim 6 of US 5,273,995
2
![Page 3: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/3.jpg)
Lessons from this case?
3
![Page 4: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/4.jpg)
First lesson:
A salt is not an acid
4
![Page 5: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/5.jpg)
5
![Page 6: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/6.jpg)
Second lesson:
Proper dependency is a life-or-death matter
6
![Page 7: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/7.jpg)
„995 patent claims 1, 2, and 6
1. [Atorvastatin acid or atorvastatin lactone or
pharmaceutically acceptable salts thereof]
2. A compound of claim 1 which is [atorvastatin acid].
6. The hemicalcium salt of the compound of claim 2.
Of this patent, Pfizer asserted only claim 6.
7
![Page 8: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/8.jpg)
8
![Page 9: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/9.jpg)
Ranbaxy argued claim 6 was invalid on several
grounds, including for failure to comply with
35 USC § 112, paragraph 4
9
![Page 10: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/10.jpg)
35 USC § 112, paragraph 4:
“Subject to the following paragraph, a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.”
• Claim 6 cannot be read to “incorporate by reference all
the limitations of the claim to which it refers”
and “then specify a further limitation of the
subject matter claimed.”
10
![Page 11: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/11.jpg)
District Court said that is not a ground for invalidity.
Federal Circuit disagreed.
• Could have written 6 to depend from 1 or as independent claim
• Precedent: Curtiss-Wright Flow Control Corp., 438 F.3d 1374, 1380 (Fed. Cir. 2006) suggested such a claim could be invalid
• No suggestion in intrinsic record that “acid” was meant to encompass corresponding salt, so unlike Merck & Co., Inc. v. Teva Pharms. USA, Inc., 347 F.3d 1367, 1372 (Fed. Cir. 2003)
11
![Page 12: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/12.jpg)
USPTO‟s new 112 ¶2 examination guidelines briefly mention that this is a ground for rejection
(see page 7166 of Federal Register Volume 76, Number 27, pages 7162-7175 (February 9, 2011))
http://www.regulations.gov/#!documentDetail;D=PTO-P-2010-0088-0001
12
![Page 13: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/13.jpg)
If you use “salt” limitation in a dependent claim,
be certain salts are explicitly covered in all base
claims up the chain
13
![Page 14: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/14.jpg)
What about solvates and polymorphs?
May depend on how independent claim is written
1. A compound of Formula A. – Should implicitly cover all solvates and polymorphs, unless prosecution estoppel
– Include disclosure in specification to make that clear
2. A composition comprising a compound of Formula A.
14
![Page 15: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/15.jpg)
“Infringement test” MPEP 608.01(n)(III):
Dependent claim is proper if it can‟t be infringed
without also infringing the claim from which it
depends.
15
![Page 16: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/16.jpg)
These dependents 2-4 are OK:
1. A compound of Formula A.
2. A method of treating diabetes, the method comprising administering to a diabetic patient an effective amount of the compound of claim 1.
3. A process of making the compound of claim 1, the process comprising reacting a compound of Formula B with acetone, thereby producing the compound of claim 1.
4. A method of generating a salt, the method comprising reacting the compound of claim 1 with X, thereby generating a salt of Formula A.
16
![Page 17: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/17.jpg)
These dependents 2-3 are NOT OK (rewrite as independent)
1. A compound having the structure of Formula A:
2. The compound of claim 1, wherein the phenyl ring is substituted with
a halogen.
3. An intermediate used in a process of making the compound of
claim 1 and having the following structure:
NH
OH
NH2
17
![Page 18: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/18.jpg)
These dependents 2-5 are NOT OK (rewrite as independent)
1. An isolated polypeptide consisting of SEQ ID NO: 2.
2. The polypeptide of claim 1, wherein the Ala at position 28 of SEQ ID NO:2 is replaced with a Leu.
3. A fragment of the polypeptide of claim 1.
4. An antibody that binds to the polypeptide of claim 1.
5. An isolated DNA that encodes the polypeptide of claim 1.
18
![Page 19: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/19.jpg)
These dependents 2-3 are NOT OK (rewrite as independent)
1. A gizmo comprising a whozit operably linked to a whatzit.
2. A machine for assembling the gizmo of claim 1, wherein the machine comprises….
3. A whozit suitable for use in the gizmo of claim 1, wherein the whozit comprises….
19
![Page 20: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/20.jpg)
Product by process 1. A process comprising reacting X with Y for 1 hour at 80°C,
thereby producing a polymer.
2. A polymer made by the process of claim 1.
• MPEP: proper dependent claim
3. The polymer set forth in claim 1.
• MPEP: not proper dependent claim
• Polymer could be made by a different process, so could
infringe claim 3 without infringing claim 1.
20
![Page 21: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/21.jpg)
So remember the lesson of Pfizer v. Ranbaxy…
21
![Page 22: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/22.jpg)
22
![Page 23: Pfizer v. Ranbaxy - Fish & Richardson v. Ranbaxy webinar 7-13... · Pfizer v. Ranbaxy, 457 F.3d 1284, 79 USPQ2d 1583 (Fed. Cir. 2006) • ANDA case regarding generic Lipitor® (atorvastatin)](https://reader031.fdocuments.in/reader031/viewer/2022022008/5ada9e7b7f8b9a86378d9a18/html5/thumbnails/23.jpg)
Janis K. Fraser, Ph.D.
Fish & Richardson P.C.
One Marina Park Drive
Boston, MA 02210
Direct dial: (617) 521-7037
23